94 related articles for article (PubMed ID: 21734413)
1. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.
Sacanna E; Ibrahim T; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Bravaccini S; Ricci R; Serra L; Amadori D
Oncology; 2011; 80(3-4):225-31. PubMed ID: 21734413
[TBL] [Abstract][Full Text] [Related]
2. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
4. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
[TBL] [Abstract][Full Text] [Related]
5. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
Mizell J; Smith M; Li BD; Ampil F; Chu QD
Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
[TBL] [Abstract][Full Text] [Related]
7. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
8. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 expression in early breast cancer and risk of distant recurrence.
Andre F; Xia W; Conforti R; Wei Y; Boulet T; Tomasic G; Spielmann M; Zoubir M; Berrada N; Arriagada R; Hortobagyi GN; Hung MC; Pusztai L; Delaloge S; Michiels S; Cristofanilli M
Oncologist; 2009 Dec; 14(12):1182-8. PubMed ID: 19939894
[TBL] [Abstract][Full Text] [Related]
10. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
11. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
12. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 membrane expression in node-negative breast cancer.
Blot E; Laberge-Le Couteulx S; Jamali H; Cornic M; Guillemet C; Duval C; Hellot MF; Pille JY; Picquenot JM; Veyret C
Breast J; 2008; 14(3):268-74. PubMed ID: 18373506
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.
Hiller DJ; Meschonat C; Kim R; Li BD; Chu QD
Surgery; 2011 Sep; 150(3):459-65. PubMed ID: 21878231
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Guarneri V; Giovannelli S; Ficarra G; Bettelli S; Maiorana A; Piacentini F; Barbieri E; Dieci MV; D'Amico R; Jovic G; Conte P
Oncologist; 2008 Aug; 13(8):838-44. PubMed ID: 18650259
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
17. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
Davidson B; Dong HP; Holth A; Berner A; Risberg B
Breast J; 2008; 14(5):476-82. PubMed ID: 18657145
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
19. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
20. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
